PWG: A Novel E-health Platform

Sponsor
Daren K. Heyland (Other)
Overall Status
Recruiting
CT.gov ID
NCT05024903
Collaborator
(none)
1,000
1
2
37
27

Study Details

Study Description

Brief Summary

The purpose of the current trial is to evaluate a novel e-health platform. Overall Hypothesis: Participants who receive Plan Well Guide (PWG) 2.0 will make more progress in their 'preparations' as measured by "Preparedness for the Future Questionnaire (PREP FQ)" at 6 months and, consequently, experience greater improvements in their psychological well-being (PWB), health status, and life satisfaction at 12 months compared to participants receiving PWG 1.0 (Advance Serious Illness module only). Study Design: The investigators propose to conduct a multi-site randomized trial to evaluate a novel e-health platform. Overall Hypothesis: Participants who receive Plan Well Guide (PWG) 2.0 will make more progress in their 'preparations' as measured by "Preparedness for the Future Questionnaire (PREP FQ)" at 6 months and, consequently, experience greater improvements in their psychological well-being (PWB), health status, and life satisfaction at 12 months compared to participants receiving PWG 1.0 (Advance Serious Illness module only).Study Design: We propose to conduct a multi-site randomized trial. Setting: Several sites in Lethbridge Alberta. a sample of primary care clinics as well as recruit online participants. Study Population: The investigators plan to include interested participants that are aged between 25 to 70 years of age. We will exclude participants that don't speak English or do not have internet access/email addresses, and already have a high PWB score. Study Intervention: Eligible participants will then be randomly allocated to 2 groups: PWG 1.0 or PWG 2.0.Outcomes: The primary outcome for this trial will be an overall score of PWB questionnaire; key secondary outcomes include PWB domain scores, SF-12,single-item rating of life satisfaction, all measured at 6 and 12 months. Additional outcomes include 'days off work' and health care utilization. Significance: This study will be the first large multi-centre trial examining the effects of a novel e-health platform aimed at improving people's psychological well-being and health status as well as their preparedness for serious illness decision-making during this time of a global pandemic. Results of this trial will likely affect the state of preparedness of individuals, and if wide disseminated, may have a dramatic effect on the health and well-being of a broad segment of the population.

Condition or Disease Intervention/Treatment Phase
  • Other: Serious illness medical planning plus the novel e-health platform (PWG 2.0)
  • Other: Standard of care
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
A Randomized Trial of a Novel E-health Platform (Plan Well GuideTM)
Actual Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Oct 31, 2023
Anticipated Study Completion Date :
Oct 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control Group: (PWG 1.0)

Those randomized to PWG 1.0 would have already completed their serious illness medical planning. Further involvement in the trial will be solely for the purposes of the outcome data collection

Other: Standard of care
Participants are not planning for their future (PWG 2.0) or using the e-health platform

Active Comparator: Intervention group: PWG 2.0

Serious illness medical planning plus the novel e-health platform designed to help people more broadly think and plan ahead

Other: Serious illness medical planning plus the novel e-health platform (PWG 2.0)
PWG 2.0 consists of the following components: A diagnostic questionnaire, "Preparedness for the Future Questionnaire" and bench-marked report that helps users assess their strengths, weaknesses and opportunities for improvement. A comprehensive e-workbook that helps users understand the science behind personal behavior change. Links to webpages with additional e-workbooks and curated content aimed to help users progress on the 30 different attitudes, behaviors, and activities that portend for a better future (topics listed in Appendix A). E-messages delivered via emails (via text an option for those that prefer) with tailored content designed to provide multiple nudges to guide the user to progress through our content. Monthly newsletter with current topics and issues related to the 30 topics and behavior change in general. A virtual consultation with Dr. Heyland, creator of PWG and principal investigator.

Outcome Measures

Primary Outcome Measures

  1. Overall Preparedness for the Future Question score [6 months]

    All scores were re-scaled to range between 0 (worst -lowest possible total points given the applica- ble answered questions) and 100 (best -highest possible total points given applicable answered questions). Measured for the Phase II trial: the questionnaire contains 34 items in 8 distinct domains ("Medico-legal", "Social", "Psychological Well-being", "Planning", "Enrichment", "Positive Health Behaviors", "Negative Health Behaviors", and "Late-life Planning")

  2. Item scores for Preparedness for the Future Question score [6 months]

    Measured for the Phase II trial

Other Outcome Measures

  1. Overall score of Psychological Well Being Scale [12 months]

    Scale is 42 to 294 and the higher scores indicate greater wellbeing

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 25-70 years old
Exclusion Criteria:
  • don't speak or read English

  • no home internet access

  • a baseline PWB score of 4.5 or greater

Contacts and Locations

Locations

Site City State Country Postal Code
1 City of Lethbridge Lethbridge Alberta Canada T1K 5T2

Sponsors and Collaborators

  • Daren K. Heyland

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Daren K. Heyland, Director of Clinical Evaluation Research Unit, Clinical Evaluation Research Unit at Kingston General Hospital
ClinicalTrials.gov Identifier:
NCT05024903
Other Study ID Numbers:
  • PWG
First Posted:
Aug 27, 2021
Last Update Posted:
Mar 22, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 22, 2022